|79.74|| +0.23 / +0.29%|
Gilead Sciences, Inc. is a biopharmaceutical company, which discovers, develops and commercializes therapeutics for unmet medical need. It focuses on human immunodeficiency virus and liver diseases, such as chronic hepatitis C virus infection & chronic hepatitis B virus infection, hematology & oncology, and cardiovascular & inflammation as well as respiratory diseases. The company's products include Descovy, Odefsey, Genvoya, Stribild, Complera, Atripla, Truvada, Viread, Emtriva, Tybost, Vitekta, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, Hepsera, Zydelig, Letairis, Ranexa, Lexiscan, Cayston, Tamiflu, AmBisome and Macugen. Gilead Sciences was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
|John F. Milligan||President, Chief Executive Officer & Director|
|Robin L. Washington||Chief Financial Officer & Executive Vice President|
|William A. Lee||Executive Vice President-Research|
|Gregg H. Alton||Executive VP-Corporate & Medical Affairs|
|Brett A. Pletcher||Secretary, Chief Compliance Officer & Executive VP|